Shahida Mallah
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Shahida Mallah has a total of 18 co-authors. Here are the top co-authors by number of shared publications:
- Ingeborg Hers
University of Bristol
3 shared publications - Changcheng Jing
School of Chemistry, University of Bristol, Cantock’s Close, Bristol BS8 1TS, U.K.
2 shared publications - James L. Hutchinson
School of Physiology, Pharmacology and Neuroscience, Faculty of Life Sciences University of Bristol Bristol UK
2 shared publications - Steven H. Bennett
School of Chemistry University of Bristol Bristol UK
2 shared publications - Stuart J. Mundell
School of Physiology, Pharmacology and Neuroscience, Faculty of Life Sciences University of Bristol Bristol UK
2 shared publications - Varinder Kumar Aggarwal
University of Bristol Cantock’s Close
2 shared publications
Latest Publications
- Open Access
- 5 June 2024
- Published by Wiley in British Journal of Pharmacology
- Vol. 181 (19) , 3685-3699
Difluorinated thromboxane A2 reveals crosstalk between platelet activatory and inhibitory pathways by targeting both the TP and IP receptors
Background and Purpose: Thromboxane A2 (TXA2) is a prostanoid produced during platelet activaton, important in enhancing platelet reactivity by activation of TP receptors. However, due to the short half‐life, studying TXA2 signalling is challenging. To enhance our understanding of TP receptor‐mediated platelet biology, we therefore synthesised mono and difluorinated TXA2 analogues and explored their pharmacology on heterologous and endogenously expressed TP receptor function.Experimental Approach: Platelet functional and signalling responses were studied using aggregometry, Ca2+ mobilisation experiments and immunoblotting and compared with an analogue of the TXA2 precursor prostaglandin H2, U46619. Gαq/Gαs receptor signalling was determined using a bioluminescence resonance energy transfer (BRET) assay in a cell line overexpression system.Key Results: BRET studies revealed that F‐TXA2 and F2‐TXA2 promoted receptor‐stimulated TP receptor G‐protein activation similarly to U46619. Unexpectedly, F2‐TXA2 caused reversible aggregation in platelets, whereas F‐TXA2 and U46619 induced sustained aggregation. Blocking the IP receptor switched F2‐TXA2‐mediated reversible aggregation into sustained aggregation. Further BRET studies confirmed F2‐TXA2‐mediated IP receptor activation. F2‐TXA2 rapidly and potently stimulated platelet TP receptor‐mediated protein kinase C/P‐pleckstrin, whereas IP‐mediated protein kinase A/P‐vasodilator‐stimulated phosphoprotein was more delayed.Conclusion and Implications: F‐TXA2 is a close analogue to TXA2 used as a selective tool for TP receptor platelet activation. In contrast, F2‐TXA2 acts on both TP and IP receptors differently over time, resulting in an initial wave of TP receptor‐mediated platelet aggregation followed by IP receptor‐induced reversibility of aggregation. This study reveals the potential difference in the temporal aspects of stimulatory and inhibitory pathways involved in platelet activation.
- 5 June 2024
- Published by Wiley in British Journal of Pharmacology
- Vol. 181 (19) , 3685-3699
Open AccessDifluorinated thromboxane A2 reveals crosstalk between platelet activatory and inhibitory pathways by targeting both the TP and IP receptors
Background and Purpose: Thromboxane A2 (TXA2) is a prostanoid produced during platelet activaton, important in enhancing platelet reactivity by activation of TP receptors. However, due to the short half‐life, studying TXA2 signalling is challenging. To enhance our understanding of TP receptor‐mediated platelet biology, we therefore synthesised mono and difluorinated TXA2 analogues and explored their pharmacology on heterologous and endogenously expressed TP receptor function.Experimental Approach: Platelet functional and signalling responses were studied using aggregometry, Ca2+ mobilisation experiments and immunoblotting and compared with an analogue of the TXA2 precursor prostaglandin H2, U46619. Gαq/Gαs receptor signalling was determined using a bioluminescence resonance energy transfer (BRET) assay in a cell line overexpression system.Key Results: BRET studies revealed that F‐TXA2 and F2‐TXA2 promoted receptor‐stimulated TP receptor G‐protein activation similarly to U46619. Unexpectedly, F2‐TXA2 caused reversible aggregation in platelets, whereas F‐TXA2 and U46619 induced sustained aggregation. Blocking the IP receptor switched F2‐TXA2‐mediated reversible aggregation into sustained aggregation. Further BRET studies confirmed F2‐TXA2‐mediated IP receptor activation. F2‐TXA2 rapidly and potently stimulated platelet TP receptor‐mediated protein kinase C/P‐pleckstrin, whereas IP‐mediated protein kinase A/P‐vasodilator‐stimulated phosphoprotein was more delayed.Conclusion and Implications: F‐TXA2 is a close analogue to TXA2 used as a selective tool for TP receptor platelet activation. In contrast, F2‐TXA2 acts on both TP and IP receptors differently over time, resulting in an initial wave of TP receptor‐mediated platelet aggregation followed by IP receptor‐induced reversibility of aggregation. This study reveals the potential difference in the temporal aspects of stimulatory and inhibitory pathways involved in platelet activation.
- Open Access
A role for SHARPIN in platelet linear protein ubiquitination and function
SHARPIN (Src homology 3 and multiple ankyrin repeat domains protein (SHANK)- associated RH domain-interacting protein) as part of the linear ubiquitin chain assembly complex (LUBAC) catalyses the addition of linear (Met1-linked) ubiquitin chains to substrates. As part of this complex SHARPIN acts as a multi-functional modulator of immune/inflammatory responses through regulation of NfkB activation. In addition, SHARPIN can act as a negative regulator of integrin function. Despite platelets being anucleate cells several studies have determined potential roles for both ubiquitination and NfkB in regulating platelet function. However, little is known about either linear ubiquitination and/or SHARPIN in mouse platelets. In this study, we evaluated platelet function in mice with impaired SHARPIN expression. We confirmed that SHARPIN was expressed in platelets from wild-type mice but not in mice homozygous for SHARPIN cpdm allele (cpdm/cpdm) and that this correlated with a reduction in linear ubiquitination. Platelet function in response to thrombin was unaffected. In contrast, CRP-XL-and U46619-mediated platelet responses and thrombus formation under flow on a collagen-coated surface were significantly reduced in the cpdm/cpdm mice. This was associated with impaired U46619-mediated intracellular signalling as well as a reduction in CRP-mediated ERK phosphorylation. Despite the reported role for NfκB in regulating platelet function, inhibiting IκBα phosphorylation did not recapitulate the cpdm/cpdm phenotype. Together, these data indicate that the lack of SHARPIN and linear ubiquitination results in impaired thrombosis and platelet functional responses to CRP and U46619. This phenotype is independent of NfκB pathway inhibition but may involve alternative signalling pathways regulated by linear ubiquitination. Key Points: SHARPIN plays an essential role in platelet linear protein ubiquitination and CRP and U46619-mediated platelet function In vitro thrombosis is significantly impaired in SHARPIN deficient mice
Open AccessA role for SHARPIN in platelet linear protein ubiquitination and function
SHARPIN (Src homology 3 and multiple ankyrin repeat domains protein (SHANK)- associated RH domain-interacting protein) as part of the linear ubiquitin chain assembly complex (LUBAC) catalyses the addition of linear (Met1-linked) ubiquitin chains to substrates. As part of this complex SHARPIN acts as a multi-functional modulator of immune/inflammatory responses through regulation of NfkB activation. In addition, SHARPIN can act as a negative regulator of integrin function. Despite platelets being anucleate cells several studies have determined potential roles for both ubiquitination and NfkB in regulating platelet function. However, little is known about either linear ubiquitination and/or SHARPIN in mouse platelets. In this study, we evaluated platelet function in mice with impaired SHARPIN expression. We confirmed that SHARPIN was expressed in platelets from wild-type mice but not in mice homozygous for SHARPIN cpdm allele (cpdm/cpdm) and that this correlated with a reduction in linear ubiquitination. Platelet function in response to thrombin was unaffected. In contrast, CRP-XL-and U46619-mediated platelet responses and thrombus formation under flow on a collagen-coated surface were significantly reduced in the cpdm/cpdm mice. This was associated with impaired U46619-mediated intracellular signalling as well as a reduction in CRP-mediated ERK phosphorylation. Despite the reported role for NfκB in regulating platelet function, inhibiting IκBα phosphorylation did not recapitulate the cpdm/cpdm phenotype. Together, these data indicate that the lack of SHARPIN and linear ubiquitination results in impaired thrombosis and platelet functional responses to CRP and U46619. This phenotype is independent of NfκB pathway inhibition but may involve alternative signalling pathways regulated by linear ubiquitination. Key Points: SHARPIN plays an essential role in platelet linear protein ubiquitination and CRP and U46619-mediated platelet function In vitro thrombosis is significantly impaired in SHARPIN deficient mice
- 10 June 2020
- Published by American Chemical Society (ACS) in ACS Central Science
- Vol. 6 (6) , 995-1000
Synthesis, Stability, and Biological Studies of Fluorinated Analogues of Thromboxane A2
Platelet activation results in the generation of thromboxane A2 (TxA2), which promotes thrombus formation by further amplifying platelet function, as well as causing vasoconstriction. Due to its role in thrombus formation and cardiovascular disease, its production is the target of antiplatelet drugs such as aspirin. However, the study of TxA2-stimulated cellular function has been limited by its instability (t1/2 = 32 s, pH = 7.4). Although more stable analogues such as U46619 and difluorinated 10,10-F2-TxA2 have been prepared, we targeted a closer mimic to TxA2 itself, monofluorinated 10-F-TxA2, since the number of fluorine atoms can affect function. Key steps in the synthesis of F-TxA2 included α-fluorination of a lactone bearing a β-alkoxy group, and a novel synthesis of the strained acetal. F-TxA2 was found to be 105 more stable than TxA2, and surprisingly was only slightly less stable than F2-TxA2. Preliminary biological studies showed that F-TxA2 has similar potency as TxA2 toward inducing platelet aggregation but was superior to F2-TxA2 in activating integrin αIIbβ3.
- 10 June 2020
- Published by American Chemical Society (ACS) in ACS Central Science
- Vol. 6 (6) , 995-1000
Synthesis, Stability, and Biological Studies of Fluorinated Analogues of Thromboxane A2
Platelet activation results in the generation of thromboxane A2 (TxA2), which promotes thrombus formation by further amplifying platelet function, as well as causing vasoconstriction. Due to its role in thrombus formation and cardiovascular disease, its production is the target of antiplatelet drugs such as aspirin. However, the study of TxA2-stimulated cellular function has been limited by its instability (t1/2 = 32 s, pH = 7.4). Although more stable analogues such as U46619 and difluorinated 10,10-F2-TxA2 have been prepared, we targeted a closer mimic to TxA2 itself, monofluorinated 10-F-TxA2, since the number of fluorine atoms can affect function. Key steps in the synthesis of F-TxA2 included α-fluorination of a lactone bearing a β-alkoxy group, and a novel synthesis of the strained acetal. F-TxA2 was found to be 105 more stable than TxA2, and surprisingly was only slightly less stable than F2-TxA2. Preliminary biological studies showed that F-TxA2 has similar potency as TxA2 toward inducing platelet aggregation but was superior to F2-TxA2 in activating integrin αIIbβ3.